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Key messages: 
1. Pelvic radiation disease is under reported and under treated 
2. Validated screening tools and treatment algorithms are available  
3. Standardised outcome measures are needed to aggregate trial results and improve the 
quality of evidence 
4. New radiation therapy techniques are developing to reduce harm to healthy tissue 
5. Specialised services in gastroenterology departments are needed 
  
Abstract 
Purpose: Pelvic Radiation Disease (PRD) in the form of chronic radiation induced consequences 
of treatment is under recognised by healthcare professionals and under reported by patients. 
Gastrointestinal symptoms are not routinely assessed, and may not be causally associated with 
previous radiotherapy. These symptoms are therefore often under treated. 
Methods: A literature search was conducted in Ovid Medline, which included Epub Ahead of 
Print, In-Process & Other Non-Indexed Citations and Ovid Embase for articles published between 
2016 and April 2018. 11 papers were selected for review. 
Results: A wide range of patient reported outcome measure instruments are used in research 
and practice. Clinical symptom grading is restricted to a fewer number of tools but may not 
always capture issues, such as urgency, that are important to the patient. Clinician and patient 
concordance in the assessment of outcomes is limited. 
Initiatives to prompt communication of the relative risks of the late consequences of treatment 
and comparative effectiveness of treatments decisions are developing, as are new techniques to 
limit irradiation of healthy tissue. 
Summary: Non-standardised outcome measurement reduces the ability to aggregate toxicity and 
patient outcomes across clinical trials. The development of standardised screening and 
treatment algorithms for gastrointestinal symptoms can systematically locate and treat 
gastrointestinal late effects of treatment.   
Keywords: Radiotherapy, gastrointestinal, outcomes, screening, consequences of treatment.  
 
Introduction 
Radical or curative treatment has been delivered to around 2.5m million people that have 
survived or are living with cancer in the UK currently, with this number predicted to increase to 
4m by 2030 [1]. Currently, around half of people with cancer have radiotherapy as part of  their 
treatment [2] and of these, many will be facing consequential effects of their treatment.  
Symptoms may be acute and transitory or long term, sometimes appearing years later [3]. A 
recent James Lind Priority setting exercise focused on Living With and Beyond Cancer called for 
more research into the late consequential effects of cancer treatment as one of its top ten 
uncertainties, How can the short-term, long-term and late effects of cancer treatments be (a) 
prevented, and/or (b) best treated/ managed? [4]. 
Pelvic radiotherapy is used in the attempt to cure a range of cancers with an estimated figure of 
17,000 patients receiving definitive or adjuvant pelvic radiotherapy per year in the UK [5].  Acute 
side effects of radiotherapy are common and most symptoms will fully resolve three months 
after the course of radiotherapy has been completed. Unfortunately, some people develop long -
term symptoms after radiotherapy and these can be permanent; symptoms that develop more 
than three months after treatment are termed ‘late effects’, but if these are the continuation of 
acute effects that do not improve, they are termed ‘consequential late effects’. The umbrella 
term of Pelvic Radiation Disease (PRD) has directed attention to this poorly understood area 
with an active patient group providing information and campaigning for greater awareness and 
research Pelvic Radiation Disease Association Additionally, Macmillan have published 
information extensively in this area with a programme dedicated to improving the outcomes for 
people suffering from late consequences of treatment. 
It has been estimated that 90% of people experiencing PRD will develop a permanent change in 
their bowel habit, and 50% of all patients receiving pelvic radiotherapy experience a reduction in 
their quality of life [6, 7]. In prostate cancer, approximately 40% of all treated patients state that 
the change in bowel function affects quality of life, and 20% or more say that this affects quality 
of life to a moderate or severe extent [7].  
Bowel problems often lead to severe difficulties for cancer survivors  (Figure 1) limiting travel, 
work and socialising. Patients may be too embarrassed to mention their symptoms or feel that 
they are an inevitable consequence of their treatment or age [8]. External beam radiation 
therapy (EBRT) treatment in particular is found to result in approximately half of patients having 
some form of bowel dysfunction; almost a third of those had consequential late effects following 
EBRT [9].  
 
Figure 1: Word cloud of patient reported late effects following radiotherapy (EAGLE study data [50])  
PRD in the form of chronic radiation-induced consequences of treatment is under recognised by 
healthcare professionals [6, 7], and under reported by patients [10]. Patients may believe that 
other clinical issues issues, such as whether their cancer has been cured, have priority in 
consultations, or are too embarrassed to raise the issue [11, 12]. Other clinicians see little utility 
in identifying gastrointestinal symptoms, for example, assuming that few treatment options 
exist, as late radiation effects were always thought to be due to permanent fibrosis and be 
irreversible. [11,12]. Therefore, gastrointestinal symptoms are not routinely assessed and may 
not be causally associated with previous radiotherapy [11, 12]. These symptoms are therefore 
often under treated, and are identified using different tools [10]. Combined with the use of non -
validated tools, and limited patient reported outcomes, there is little opportunity to aggregate 
outcomes and results across trials [13].  
This review will consider selected literature from 2016 to 2018 to understand the assessment 
and treatment of consequential effects of radiotherapy on bowel function.  
 
Methods 
A literature search was conducted in Ovid Medline which included Epub Ahead of Print, In -
Process & Other Non-Indexed Citations and Ovid Embase for articles published between 2016 
and April 2018. The search strategy was designed using both text words and Medical subject 
headings (Table 1). 
Table 1: Search Strategy. 
 
Sixty five records were screened after removing duplicates and irrelevant references. Thirty nine 
full-text articles assessed for eligibility and 11 papers of particular interest were included in the 
review (Figure 2). Of these, data from more than 20,000 people were included in 11 papers 
(Table 2) reporting randomised controlled trials or follow up results, reviews of the literature, 
and cohort studies. Radiation treatments included External Beam Radiation Therapy (EBRT), 
External Megavoltage Radiotherapy (EMRT), Brachytherapy, hypofractionated IMRT (HIMRT), 
Hypofractionated High Dose Intensity Modulated Radiotherapy (HFRT), Stereotactic Ablative 
Radiotherapy (SABR), and Proton Therapy (PT).  
 
Figure 2. Study flow Diagram 
 
Overview of selected papers 
Within the selected literature, 9 of 11 papers focused on prostate cancer, perhaps not 
surprisingly, given the high incidence, its large surviving population, and high number of clinical 
trials. Rectal and colorectal cancer were also included. The range of  follow-up periods to assess 
consequences of treatments ranged between one year to ten years, where this was stated.  
A range of study designs are included, CTIMPs, RCTs and follow up reporting, cohort and 
observational, registry data or narrative literature review. Interventions include medicinal 
products, dose escalation, new radiation therapies and novel techniques.  
Table 2. Included papers. 
 
The papers report toxicities outcomes following radiation therapy using a range of measures 
(Table 3), including clinician assessed grading of symptoms LENT/SOMA [14, 15], CTCAE [16] and 
RTOG [17] and patient reported outcome measures, including IPSS [18], EPIC [19], QLQ C30 [20], 
QLQ PR25 [21], FACT-G [22], SF12 [23], EPIC 26 [24]).  
Some studies did not specify patient outcome measures [25] or used non validated PROMS 
(**26) or pragmatic data collection methods including non-validated questionnaires. One study 
constructed a single question ‘overall how much does your bowel function affect your quality of 
life [**27].  
Five studies used both clinician and patient reported outcome measures to assess symptoms 
[25, *28,*29, 30,**31], the remainder reported patient reported outcomes only.  
Table 3. Symptom and QoL measurement tools. 
 
Risk assessment, comparative effectiveness and treatment decision-making  
Two papers paid attention to aspects relating to treatment decision-making via the competing 
risks of treatments, including late effects [**26], or how treatment decisions were made [**27]. 
Both papers explored how the potential for late effects and comparative harms of treatment 
modalities is communicated to the patient [**26, **27]. Suggested interventions included pre-
treatment counselling regarding risk of harm, and use of a nomographic consent aid, designed 
by patients, showing the predicted percentages of affected bowel function according to 
associated variables of disease and treatment.  However, in a narrative synthesis of trials of 
interventions for prostate cancer, it was acknowledged that the evidence base for the clinical 
effectiveness of treatments, including surgery or radiotherapy, is weak due to underpowered 
clinical trials and differing assessment measures, thereby further complicating treatment 
decision-making [*32]. In a narrative synthesis of the literature looking at quality of life 
outcomes following a broader range of treatments for prostate cancer (including active 
surveillance (AS)), the research team focused on validated patient reported outcome measures 
(PROMS) exclusively [*33]. The study confirms similar outcomes [*32] with reported QoL issues 
specific to treatment modalities: surgery/urosexual symptoms, EBRT/ bowel symptoms, 
Brachytherapy/short term urinary symptoms, whilst AS is associated with high scores f or QoL.  
In terms of concordance of clinician vs patient reported outcomes, one paper noted the 
disparity between the clinician and patient assessments [*29] (albeit using a non-validated 
questionnaire), especially in relation to urgency, which was noted as an enduring effect 
observed in 7% of men at three years post EBRT for prostate cancer [15].   
Given the lack of aggregated outcome sets, and in support of treatment decision –making with 
regard to QoL, a group based in Melbourne have established a clinical registry to collect and 
analyse patient-centred outcomes [**31]. Men with prostate cancer are routinely telephoned 
about health outcomes and QoL using questions from validated QoL tools at 12 and 24 months 
from diagnosis. An analysis of patient data from 1825 men revealed outcome differences 
between treatment centres enabling a further evaluation of centres not matching the standard 
of others. 
Limiting effects of treatment 
The incidence and grade of gastrointestinal toxicity is associated with radiation dose and volume 
of irradiated healthy bowel tissue [3] and the importance of reducing toxicities of treatment and 
preserving QoL are key concerns in managing existing treatments or developing new treatments. 
These include new techniques of targeted radiation therapy, which aims to reduce the volume 
of sensitive normal tissues being irradiated, and trials of drugs that may protect healthy tissue 
have been reported recently. 
Some populations may be under represented in clinical trials, a lack of racial diversity [**26] or a 
narrow age range increases the risk of trials bias or incorrect assumptions about treatment 
tolerance. The CHHiP trial found that hypofractionated high dose intensity modulated radiation 
therapy for prostate cancer is non inferior to conventional treatment. In an exploratory analysis 
and in an exploratory analysis [*34], reported on the outcomes of 491 men aged 75+, 
constituting 15% of the trial participants, and concluded that the treatments were well tolerated 
and that age should not be a barrier to treatment. Of interest is the fact that patient reported 
outcomes increased the reporting of bowel bother, which were not reported in the outcomes 
measured by validated symptom questionnaires, including RTOG and LENT-SOMA.  
Proton beam therapy (PBT) may result in less damage to surrounding tissue due to targeted 
treatment and lack of exit dose but has a limited evidence base in terms of patient outcomes. 
One treatment centre has retrospectively reviewed its first 100 patients receiving PBT for 
prostate cancer [*28]. Late outcomes for 79 patients were reported after a minimum of three 
months using clinical grading (CTCAE v.4) [35] in combination with PROMS (IPSS and EPIC). Both 
sets of outcomes compare favourably to photon therapy but the evidence is limited due to the 
small, heterogenous study population. 
In a phase II randomised controlled trial of treatment delivery with the use of a hydrogel spacer 
to protect the rectal wall,  GI toxicities were reduced and QoL scores were improved after f ive 
years in 54 patients with prostate cancer [*36]. However, for an NHS setting, the high cost of 
injections may be prohibitive. 
Despite advances in treatment dose distribution and techniques, damage to rectal tissue still 
occurs. A different approach sees the potential for protection of the tissue using Lovastatin, a 
drug which has the ability to protect mice from the late effects of radiation treatment. 
Unfortunately, when tested in a non randomised trial of 53 adults with prostate cancer, it was 
not effective [25].  
Conclusion 
Communication of the risk of late effects of radiation therapy is increasingly complex. 
Gastrointestinal late effects can be debilitating and in the interests of patient -centred health 
care, communication of potential risk is essential to shared decision –making. Additionally, due 
to the lack of a standardised approach to measuring patient outcomes, aggregation of data 
across clinical trials and clinical settings is not feasible, leading to low evidence of the toxicities 
associated with radiation therapy interventions.  
New techniques to improve the preservation of healthy tissue are developing rapidly, including 
focal salvage for prostate cancer, which aims to avoid whole gland exposure to radiation, with 
tentative evidence that GI and erectile toxicities are reduced [30]. However, awareness of the 
potential for consequences of treatment is essential. Late radiation effects may be perceived by 
clinicians as irreversible, with limited treatment options. Clinicians may not actively see k 
information on late radiation effects, focussing primarily on symptoms of cancer [11, 12]. 
Patients, viewing symptoms as expected consequences of therapy, or being too embarrassed to 
mention them, or grateful for curative treatment may not volunteer their symptoms during 
consultations, regardless of the ongoing effects on their physical, psychological and social 
wellbeing. Enabling patients to report symptoms as a matter of course and consistent 
assessment by clinicians, is key to fully understanding the extent of the issue, and ultimately 
improving long term patient care.   
For a screening tool to be effective in a busy clinical setting, the questionnaire should be 
succinct and simple. The Late Effects on Normal Tissue Subjective, Objective, Management, a nd 
Analytic (LENT-SOMA) questionnaire (now largely superseded by Common Terminology Criteria 
for Adverse Events [CTCAE] [16], was developed to assess a wide range of problems after 
radiotherapy [37]. However, despite efforts to reduce the length of this questionnaire [38], it is 
too long to be used routinely as a screening tool [37]. Other symptom grading scoring systems 
are also either too long (e.g. the modified Inflammatory Bowel Disease Questionnaire [IBDQ] 
[39]  with 32 items and the Gastrointestinal Symptom Rating Scale [GSRS] [39, 40, 41, 42, 43]  
with 15 items, or they focus on just one symptom (e.g. the Vaizey Incontinence Questionnaire 
with seven items focussing on bowel continence) [42]. Therefore, there is a need for a simple 
screening tool that can be used in clinical practice.  
Screening 
ALERT- B (Figure 3) is a three question validated tool that can effectively detect patients with 
ongoing gastrointestinal symptoms that have developed after pelvic radiotherapy for cancer  
[44]. The tool is specified in the latest version of the Royal College of Radiologists 'Modernising 
radiotherapy services in England' (forthcoming) and can be used at any time post pelvic 
radiation therapy.  
 
Figure 3: Alert-B Screening Tool questions 
Treatment 
Research carried out at the Royal Marsden Hospital (RMH), has identified 23 symptoms that 
frequently occur after prostate radiotherapy [11, 12]. A sophisticated algorithm has been 
developed that allows these symptoms to be managed in a systematic way [45]  and tested in 
The Optimising Radiotherapy Bowel Injury Therapy (ORBIT) trial for pelvic cancer (prostate, 
bladder, vulvar, vaginal cervical, endometrial, anal and rectal cancer) [45, 46, 47, 48]. The trial 
has shown that these symptoms can be accurately diagnosed and effectively treated at low cost 
with high benefit to the patient [46, 47]. The ORBIT trial has also demonstrated that specialist 
trained nurses can deliver this assessment and treatment as effectively as a doctor in most 
patients. Other centres trialling the algorithm have also found it to effectively improve patients’ 
symptoms at modest cost [49, 50] and have highlighted the need for specialized services 
embedded within gastroenterology.  
 
Late effects of treatment can occur months or years later, which emphasises the need for 
consistent and timely assessments at key points. Given that many patients may be lost to follow -
up whilst there symptoms occur, one solution would be to place an assessment directly in the 
hands of the patient. The Alert B tool is currently being tested as a patient reported outcome 
measure available on a commercial electronic patient platform. This work is ongoing in England 
and Wales as a collaboration between Macmillan and the Royal College of Radiologists.   
PRD is an under recognised and under treated consequence of radiation therapy. However, 
ongoing work to screen and treat gastrointestinal symptoms, and the development of new 
techniques to limit damage to healthy tissue during radiation therapy will increase awarene ss 
and support a reduction in the incidence of this distressing condition.  
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